Question explored with the scientific record
TUDCA (tauroursodeoxycholic acid) Is it safe for breast feeding mother with gallstones
The short version: the evidence does not answer your question. No study in this retrieval tested TUDCA in a breastfeeding mother with gallstones.
The evidence you have is a pile of lab experiments on rat liver cells [3, 5, 6, 8], human liver cells in a dish [10], and human neutrophils [7]. One study gave TUDCA to sick newborns on IV nutrition [1], but those babies were not breastfed and did not have gallstones. Another study measured TUDCA levels in gallbladder bile of adults with gallstones [2], but that is a measurement, not a safety trial. The rest are about skin cells [4], Parkinson's disease in mice [9], and breast-milk bacteria [11, 13] — none of which test what happens when a nursing mother takes TUDCA.
The gap is wide. No study tracked TUDCA levels in breast milk. No study followed infants exposed through milk. No study compared gallstone outcomes in breastfeeding women who took TUDCA versus those who did not. The mechanism is plausible — TUDCA is a bile acid that dissolves cholesterol stones and protects liver cells — but plausible is not proven safe for a nursing infant.
| What was studied | Population | Does it answer this question? |
|---|---|---|
| TUDCA in rat liver cells [3, 5, 6, 8] | Rats | No |
| TUDCA in human liver cells in a dish [10] | Cells in lab | No |
| TUDCA in sick newborns on IV nutrition [1] | Hospitalized neonates | No |
| TUDCA levels in gallstone patients [2] | Adults with stones | No |
| TUDCA for Parkinson's in mice [9] | Mice | No |
My call: the evidence is too thin to say TUDCA is safe for a breastfeeding mother with gallstones. The missing data — milk levels, infant outcomes, long-term follow-up — means the burden of proof has not been met. Confidence: low.
Sources used 13
-
Tauroursodeoxycholic acid (TUDCA) in the prevention of total parenteral nutrition-associated liver disease
This study investigates the efficacy of tauroursodeoxycholic acid (TUDCA) in preventing or ameliorating liver injury in neonates receiving total parenteral nutrition (TPN), finding no significant differences in liver function markers between TUDCA-treated and control groups.
DOI: 10.1067/mpd.2002.125802 -
Conjugated Bile Acids in Gallbladder Bile and Serum as Potential Biomarkers for Cholesterol Polyps and Adenomatous Polyps
Conjugated bile acids in gallbladder bile and serum may distinguish cholesterol polyps from adenomatous polyps, suggesting potential noninvasive biomarkers for gallbladder polyps.
DOI: 10.5301/jbm.5000173 -
Effect of tauroursodeoxycholic acid on bile-acid-induced apoptosis and cytolysis in rat hepatocytes
This study investigates the effects of tauroursodeoxycholic acid on bile-acid-induced apoptosis and cytolysis in primary rat hepatocytes, demonstrating its protective role against liver damage caused by hydrophobic bile acids.
DOI: 10.1016/s0168-8278(98)80208-0 -
Taurin-conjugated ursodeoxycholic acid has a reversible inhibitory effect on human keratinocyte growth
This study investigates the reversible inhibitory effect of Tauroursodeoxycholic acid (TUDC) on the growth of human keratinocytes, demonstrating its potential application in treating hyperproliferative skin disorders such as psoriasis.
DOI: 10.1016/S0923-1811(98)00023-1 -
Regulation of MDR2 P-glycoprotein expression by bile salts
The study investigates the effects of tauroursodeoxycholic acid (TUDCA) on protein kinase C (PKC) activity in isolated rat hepatocytes, demonstrating that TUDCA stimulates PKC primarily through the membrane-bound fraction, which may mediate hepatocellular exocytosis.
DOI: 10.1016/0270-9139(95)95012-5 -
Hepatoprotection in ethinylestradiol‐treated rats is provided by tauroursodeoxycholic acid, but not by ursodeoxycholic acid*
This study investigates the hepatoprotective effects of tauroursodeoxycholic acid (TUDCA) compared to ursodeoxycholic acid (UDCA) in ethinylestradiol-treated rats, demonstrating that TUDCA provides significant protection against liver damage while UDCA does not.
DOI: 10.1111/j.1440-1746.1995.tb01091.x -
Tauroursodeoxycholic acid inhibits the cytosolic Ca++ increase in human neutrophils stimulated by formyl-methionyl-leucyl-phenylalanine
This study investigates the inhibitory effects of tauroursodeoxycholic acid (TUDCA) on cytosolic calcium increases in human neutrophils stimulated by formyl-methionyl-leucyl-phenylalanine.
DOI: 10.1016/0006-291x(90)90800-3 -
Substitution of ursodeoxycholate (UDC) for toxic bile salts ameliorates mitochondrial damage caused by bile salts and calcium
The study investigates the effects of tauroursodeoxycholic acid (TUDCA) on diacylglycerol (DAG) mass in isolated rat hepatocytes, revealing that TUDCA and other bile acids stimulate DAG formation, which may mediate hepatocellular exocytosis.
DOI: 10.1016/0016-5085(95)28442-7 -
Nrf2 activation by tauroursodeoxycholic acid in experimental models of Parkinson's disease
This study investigates the neuroprotective effects of tauroursodeoxycholic acid (TUDCA) in experimental models of Parkinson's disease, demonstrating its ability to activate the Nrf2 signaling pathway and mitigate oxidative stress-induced damage.
DOI: 10.1016/j.expneurol.2017.05.009 -
Effect of tauroursodeoxycholic acid on bile acid‐induced apoptosis in primary human hepatocytes
Co-incubation with equimolar tauroursodeoxycholic acid (TUDCA) reduces GCDCA-induced DNA fragmentation in primary human hepatocytes at 50 mM GCDCA, indicating a protective effect of TUDCA against bile acid–induced apoptosis independent of Fas signaling.
DOI: 10.1046/j.1365-2362.2000.00615.x -
Characterization of Candidate probionts isolated from human breast milk
This study isolates bacteria from healthy human breast milk, characterizes their probiotic properties (antibacterial activity, acid/bile tolerance, simulated gastric/intestinal transit, and adhesion to Caco-2 cells), and identifies candidate infant probiotics, while noting limit…
DOI: 10.14715/cmb/2017.63.5.15 -
Late neonatal vitamin K deficiency associated with subclinical liver dysfunction in human milk-fed infants
A study of late neonatal vitamin K deficiency in predominantly human milk–fed infants demonstrates that subclinical liver dysfunction and fat-malabsorption due to cholestasis, not just low breast-milk vitamin K, contribute to deficiency, with vitamin K treatment yielding general…
DOI: 10.1016/s0022-3476(89)80704-8 -
Temporal Associations Between Human Milk Metabolites and the Infant Gut Microbiome and metabolome
A longitudinal multi-omics study in the FinnBrain birth cohort (infants at 2.5, 6, and 14 months) investigates how human milk metabolites relate to the infant gut microbiome and its metabolome, finding time-dependent associations with specific taxa and fecal metabolites while ov…
DOI: 10.1101/2025.10.28.681130